Literature DB >> 7576317

Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E.

C Wasi1, B Herring, S Raktham, S Vanichseni, T D Mastro, N L Young, H Rübsamen-Waigmann, H von Briesen, M L Kalish, C C Luo.   

Abstract

OBJECTIVES: To evaluate the sensitivity and specificity of peptide-binding enzyme immunoassay (PEIA) and heteroduplex mobility assay (HMA) for the determination of HIV-1 subtypes B and E; to determine the proportions of infections due to subtypes B and E over time; and to generate data on DNA sequences of the C2-V3 region of the env genes.
METHODS: HIV-1 subtyping was conducted by PEIA and HMA on blood specimens obtained from 97 injecting drug users (IDU) infected with HIV between 1988 and 1993. Genetic sequencing was performed on 84 specimens.
RESULTS: Both laboratory methods were highly sensitive and specific for the determination of HIV-1 subtypes B and E. The two tests were complementary; samples which could not be typed by HMA were correctly typed by PEIA and vice versa. While subtype B accounted for 80.4% (78 out of 97) of infections overall, the proportion of new infections due to subtype E increased from 2.6% (one out of 38) in 1988-1989 to 25.6% (11 out of 43) in 1990-1991, and to 43.8% (seven out of 16) in 1992-1993 (chi 2 for linear trend, P < 0.001).
CONCLUSIONS: HMA and PEIA are practical, sensitive and specific laboratory methods for the determination of HIV-1 subtypes in Thailand, and may be useful in other geographic areas to define the molecular epidemiology of the global HIV-1 pandemic. Data suggest that the proportion subtype E infections have increased among Bangkok IDU from 1988 through 1993.

Entities:  

Keywords:  Asia; Behavior; Developing Countries; Diseases; Drug Usage; Examinations And Diagnoses; Genetic Technics; Hiv; Hiv Infections; Iv Drug Users; Laboratory Examinations And Diagnoses; Laboratory Procedures; Research Report; Southeastern Asia; Thailand; Viral Diseases

Mesh:

Substances:

Year:  1995        PMID: 7576317     DOI: 10.1097/00002030-199508000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  14 in total

1.  Position and degree of mismatches and the mobility of DNA heteroduplexes.

Authors:  D A Upchurch; R Shankarappa; J I Mullins
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Inferring viral population structures using heteroduplex mobility and DNA sequence analyses.

Authors:  Raj Shankarappa; James I Mullins
Journal:  J Virol Methods       Date:  2013-08-29       Impact factor: 2.014

4.  Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.

Authors:  Gustavo H Kijak; Sodsai Tovanabutra; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirapa Eamsila; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Chawetsan Namwat; Nakorn Premsri; Michael Benenson; Patricia Morgan; Meera Bose; Eric Sanders-Buell; Robert Paris; Merlin L Robb; Deborah L Birx; Mark S De Souza; Francine E McCutchan; Nelson L Michael; Jerome H Kim
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

5.  Development of an env gp41-based heteroduplex mobility assay for rapid human immunodeficiency virus type 1 subtyping.

Authors:  S M Agwale; K E Robbins; L Odama; A Saekhou; C Zeh; A Edubio; O M Njoku; N Sani-Gwarzo; M F Gboun; F Gao; M Reitz; D Hone; T M Folks; D Pieniazek; C Wambebe; M L Kalish
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

6.  V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant.

Authors:  J C Plantier; F Damond; S Souquières; F Brun-Vézinet; F Simon; F Barin
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

7.  Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E.

Authors:  J P Anderson; A G Rodrigo; G H Learn; A Madan; C Delahunty; M Coon; M Girard; S Osmanov; L Hood; J I Mullins
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand.

Authors:  J K Carr; M O Salminen; C Koch; D Gotte; A W Artenstein; P A Hegerich; D St Louis; D S Burke; F E McCutchan
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.